



American Society for Quality (www.asq.org) – Washington DC and Maryland Metro, Section 509 (www.asq509.org)

Biomed/Biotech Special Interest Group (SIG) Meeting

“Building a Competitive Biologics Pipeline Portfolio through Novel Technologies”

To be presented by

Herren Wu, PhD
(WuH@MedImmune.com)

Vice President, Research & Development
Head, Antibody Discovery & Protein Engineering
MedImmune

Thursday, April 25, 2013

6:00 – 6:20 PM – Networking; Pizza/drink

6:20 – 8:30 PM – Program (intermission at 7:40 pm)

8:30 – 8:45 PM – Door-prizes drawing; Networking

Online Registration site: <http://www.asq509.org/ht/d/DoSurvey/i/35817>

Open to Public –

\$5: non-ASQ members to cover pizza/drink cost;

Free: ASQ members, MJ-DC members, CAPA-DC members, veterans, senior citizens, students, interns, residents, postdocs, FDA Commissioner’s Fellows, and current job-seekers

Location: Kelly’s Deli Conference Center, 7519 Standish Place, Rockville (Derwood, for GPS user), MD 20855

Registration Deadline: Please register by **Thursday noon, April 25, 2013.**

Question: Please contact Dr. C.J. George Chang, Chair of Biomed/Biotech SIG, ASQ509; gchang2008@yahoo.com or 240-793-8425 (cell).

Driving directions: By Cars: From I-270 (N or S bound): Take Exit 9A and exit from the FIRST right exit; turn left (east) onto Shady Grove Dr.; turn right (south) onto Rockville Pike (**Route 355**); turn left (east) onto East Gude Dr.; turn left (north) immediately onto Crabb’s Branch Dr.; turn left (west) immediately onto Standish Place. The first building on your right side is 7519 Standish Place; open parking). The venue is on the first floor with its entrance opposite to the left side of building main entrance. **By Metro trains:** Off from Red Line **Shady Grove Station**, and take RideOn **Route 59 TOWARD ROCKVILLE** and get off from “**Calhoun Place**” stop. Standish Place is next to the Bus stop. Our venue is within 2 min of walking distance from the stop.

Summary:

In the past three decades, biotech has evolved into an industry which plays a significant role in the health care system by providing effective drugs for the treatment of human disease. In the coming few years, biotech products, in particular antibodies, are projected to dominate the top ten drug list in terms of annual worldwide sale. Such success is the result of the cumulation of three decades of innovation in the industry. Looking forward, to ensure continued success and competitiveness, biotech needs to maintain its tradition of generating and embracing break-through innovations by taking risk to develop novel drugs for unmet medical needs.

In this presentation, I will share some of our experience in applying cutting-edge technologies to generate novel therapeutic biologics that have great potential in the treatment of cancer, asthma, autoimmune, and infectious diseases.

Presenter's Bio:

Dr. Herren Wu is **Vice President** of R&D and **Head** of antibody discovery/protein engineering in *MedImmune*, the global biologics arm of AstraZeneca. In this position, he is responsible for global technology, antibody discovery, antibody/protein engineering, therapeutic peptides, protein scaffolds, production cell line generation, protein sciences, and structural biology. He leads a global organization of 210+ scientists. He is actively involved in developing MedImmune's clinical- and preclinical-stage product candidates for infectious diseases, cancers, autoimmune diseases, inflammation, respiratory diseases, CV/metabolic diseases and CNS/pain. In addition, he also has the responsibility in co-leading MedImmune's Asia biologics R&D strategy.

Dr. Wu has about 20-year experience in antibody/protein drug discovery and development. He started as **Director**, protein engineering and structure in MedImmune in 2002. He was promoted to **Senior Director**, head, antibody discovery and protein engineering in 2004 and vice president in 2007. Prior to joining MedImmune, he served as **Head**, molecular biology department at *Tanox, Inc.* (acquired by Genentech in 2007). Before joining Tanox, he held a variety of research positions up to **Associate Director**, antibody engineering and discovery at *Applied Molecular Evolution* (now a subsidiary of Eli Lilly & Co.). He is the **recipient** of the Senior Technology Fellow Emerald Honors award presented at the 2006 Minorities in Research Science Conference. He is also named as **co-inventor** on 35 issued patents and 34 patent applications related to antibody/protein therapeutics and technologies.

Dr. Wu received his bachelor's degree (1986) in chemistry from the National Taiwan University, Taipei, Taiwan, ROC and his doctorate (1993) in molecular and cellular biology from the University of Massachusetts, Amherst, MA. He completed his postdoctoral training (1995) at The Scripps Research Institute in La Jolla, California.

This event is cosponsored by the Monte Jade Science and Technology Association of Greater Washington (www.MonteJadeDC.org) and the Chinese American Professionals Association (www.capadc.org).